Ilenia Migliaccio

Azienda Usl Toscana Centro — Italy

Medicine · Health Sciences

30h-index3.3kcitations169works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Advanced Breast Cancer Therapies(90), Estrogen and related hormone effects(42), HER2/EGFR in Cancer Research(39), Cancer-related Molecular Pathways(31), Lung Cancer Research Studies(25)

Publications169 total

Abstract PS2-07-13: Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures for patients with early breast cancer treated with endocrine therapy with or without palbociclib in the PALLAS trial (ABCSG-42, AFT-05, BIG 14-03)
Clinical Cancer Research·2026
A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing
Genome Medicine·2026Open Access
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines
npj Breast Cancer·2025· 1 citedOpen Access
Abstract P1-03-20: Role of MCM2 and the licensing complex in predicting endocrine and CDK4/6 inhibitor resistance in ER+ breast cancer
Clinical Cancer Research·2025
Abstract P4-05-29: ctDNA and serum thymidine kinase activity as tools to stratify ER+/HER2- metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibitors: preliminary results of the TIRESIAS trial
Clinical Cancer Research·2025
52P Dynamics of ctDNA and serum thymidine kinase activity in patients with ER+/HER2- metastatic breast cancer receiving abemaciclib vs palbociclib or ribociclib: Early results of the TIRESIAS trial
ESMO Open·2025· 1 citedOpen Access
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer
npj Breast Cancer·2025· 5 citedOpen Access
CDK4/6 Inhibitor Resistance in ER+ Breast Cancer
Advances in experimental medicine and biology·2025· 3 cited
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
The Breast·2024· 10 citedOpen Access
The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?
Annals of Oncology·2024Open Access
Sensitive tumor detection, accurate quantification, and cancer subtype classification using low-pass whole methylome sequencing of plasma DNA
2024· 1 citedOpen Access
Abstract PO1-07-02: Sensitive tumor detection, accurate quantification, and ER subtyping using low-pass methylome of liquid biopsy samples from patients (pts) with metastatic breast cancer (mBC)
Cancer Research·2024
Abstract PO3-13-02: Genomic and intrinsic subtype correlates of serum thymidine kinase activity in patients with metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial
Cancer Research·2024Open Access
Abstract PO2-16-02: RBsig gene-expression signature in patients with endocrine resistant metastatic breast cancer treated with palbociclib and fulvestrant in the PYTHIA trial
Cancer Research·2024Open Access
239P Genomic landscape of metastatic ER+/HER2- breast cancer (BC) with loss of estrogen (ER) and/or progesterone (PR) receptor
ESMO Open·2024· 1 citedOpen Access
45P Integrated multi-omic analysis of HR+/HER2- breast cancer cell lines resistant to CDK4/6 inhibitors
ESMO Open·2024Open Access
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial
JCO Precision Oncology·2024· 4 citedOpen Access
2272P Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Annals of Oncology·2023· 2 citedOpen Access
Supplementary Figure 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
Supplementary table 2 from Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance
2023Open Access
page 1 of 9Next →

Frequent Co-authors

Luca Malorni(33), Angelo Di Leo(25), Matteo Benelli(19), Chiara Biagioni(17), Laura Biganzoli(15), Martina Bonechi(15), Cristina Guarducci(14), Amelia McCartney(14), Emanuela Risi(11), Susan G. Hilsenbeck(9), Rachel Schiff(9), Dario Romagnoli(9), C. Kent Osborne(8), Francesca Galardi(7), Erica Moretti(7), Francesca De Luca(6), Giulia Boccalini(6), Giancarlo Troncone(5), Lucio Palombini(5), Alessia Caleo(4)